Evaluating body composition—including lean mass, fat mass, muscle function, and BMD—is a critical component of care that merits further research and outcome data analysis for patients receiving GLP-1 RAs for the spectrum of impaired glucose tolerance, early T2D, T2D and obesity. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.